Level D· Scientific groundwork from lab and animal studiesAnimal StudyPubMed

Exosomes from adipose derived mesenchymal stem cells alleviate diabetic osteoporosis in rats through suppressing NLRP3 inflammasome activation in osteoclasts.

Zhang L., Wang Q., Su H., Cheng J.

Animal Study on Systemic / IV, published in J Biosci Bioeng (2021) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
J Biosci Bioeng (2021)
Country
Japan
Reported sample size
—
Source database
PubMed
PMID
33849774
DOI
10.1016/j.jbiosc.2021.02.007
Citations
86

Abstract (original English)

Inflammation is one of major contributors of diabetic osteoporosis. Adipose derived mesenchymal stem cells (AD-MSCs) show great potential to inhibit inflammation. We investigated the anti-osteoporosis role of AD-MSCs-derived exosomes in diabetic osteoporosis and the underlying molecular mechanism. Cellular and animal diabetic osteoporosis models were created through high glucose exposure and streptozotocin injection. AD-MSCs-derived exosomes were isolated and characterized. Pro-inflammatory cytokines and osteoclast markers were determined by ELISA. Bone mineral content and density were detected to evaluate bone loss. qRT-PCR and Western blots were performed to detect the expression of target genes. AD-MSCs-derived exosomes inhibited the secretion of IL-1β and IL-18 in HG treated osteoclasts and restored the bone loss in streptozotocin-induced diabetic osteoporosis rats. Mechanistically, AD-MSCs-derived exosomes suppress NLRP3 inflammasome activation in osteoclasts, and then reduce bone resorption and recover bone loss. AD-MSCs-derived exosomes alleviate diabetic osteoporosis through suppressing NLRP3 inflammasome activation in osteoclasts, which might be a potential cell-free therapeutic approach for diabetes-induced bone loss treatment.

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence
AnimalsCells, CulturedCytokinesDiabetes Mellitus, ExperimentalExosomesInflammasomesMaleMesenchymal Stem CellsNLR Family, Pyrin Domain-Containing 3 ProteinOsteoclasts

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research